Invex Therapeutics Ltd has released a press release.
Invex to close IIH Evolve Phase III Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Invex Therapeutics Ltd. on 6ix
Story so far
Earlier from Invex Therapeutics
- Phase III Clinical Trial Update and New IIH Market Analysis
- Invex Granted European Orphan Drug Designation for TBI
- Invex Receives Regulatory Approval for IIH EVOLVE in France
- Israel Ministry of Health Approval for IIH EVOLVE
- German Approval for IIH EVOLVE Phase 3 Clinical Trial
Later from Invex Therapeutics
- Invex issued US patent for Traumatic Brain Injury
- Proposed Capital Return to Shareholders of $14.0 Million
- Invex Granted European Patent for Exenatide in Hydrocephalus
- Invex and Peptron Mutually Terminate Manufacturing Agreement
- Appendix 4D and Half year report
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics